【摘要】 目的:应用蛋白质组学技术探寻宫颈癌相关抗原。方法:先用双向电泳(2-DE)分离宫颈癌患者的癌组织和癌旁正常组织中抽提的蛋白质混合物,再以免疫印迹将凝胶上的蛋白质转移到尼龙膜,继而与患者血清杂交显色后通过比较两者的反应性来筛选目的蛋白,最后运用质谱技术鉴定目的蛋白。结果:组织蛋白经2-DE分离、转膜后与患者血清杂交、显色,癌组织来源的蛋白质呈阳性反应。对应的癌旁正常组织来源的蛋白质呈阴性反应的蛋白质点有4个,切取其中1个经质谱鉴定为β微管蛋白Ⅳb(Beta tubulin Ⅳb)。β微管蛋白Ⅳb在宫颈癌患者体内发生体液免疫产生了抗体。结论:β微管蛋白Ⅳb可能是宫颈癌的相关抗原;蛋白质组学技术与血清学相结合是探寻肿瘤相关抗原的新方法。更多还原

【Abstract】 Objective:To implement a proteomic approach for the identification of tumor antigens in cervical carcinoma.Methods:At first,proteins from cervical carcinoma tissues and surrounding normal tissues adjacent to tumor were separated by two-dimensional PAGE.Then proteins were transferred to poly membranes.Sera from the same patients with cervical carcinoma were screened for IgG and IgM autoantibodies against the proteins by Western blot analysis.Finally,mass spectrometric analysis system was used to identify the constituents of the positive proteins.Results:Cervical carcinoma patient’s sera reacted with the four proteins from carcinoma tissues,but didn’t react with the same proteins from paired normal tissues.One of these proteins was identified by mass spectrometric analysis as beta tubulin Ⅳb.The findings indicated that patients with cervical carcinoma commonly develop a humoral response against beta tubulin Ⅳb.Conclusion:Beta tubulin IVb may be a tumor-associated antigen of cervical carcinoma.Serological proteomic analysis may be a new approach for the identification of tumor-associated antigens.更多还原